Dec 24, 2007, 01.42 PM | Source:

Mohan Bhandari receives Life-time Achievement Award

Mohan Bhandari receives Life-time Achievement Award at 59th IPC Conference held at BHU, Varanasi. This honour is bestowed upon stalwarts who have brought a significant difference to the Indian pharmaceutical industry and elevated it to a global level.

Mr. Mohan Bhandari, Chairman and Managing Director, Bilcare Ltd. was felicitated with the Life-time Achievement Award during the 59th IPC conference being held here from Dec 21 – 23, 2007. The award was presented to Mr. Bhandari by Dr. John L. LaMattina, Senior Vice-President Pfizer Inc and President Pfizer Global Research and Development, who was the guest of honour at the function. This honour is bestowed upon stalwarts who have brought a significant difference to the Indian pharmaceutical industry and elevated it to a global level.


Mr. Bhandari laid the foundation of Bilcare Ltd. 20 years ago, in 1983 with the vision to build leadership in the pharmaceutical packaging industry. Under his able leadership, the company has grown manifold, went public and acquired companies in US, Europe and Asia and attained leadership position in the country. Mr. Bhandari was also instrumental in starting a new division of the company, namely (GCS) Global Clinical Services.


Under the leadership of Mr. Bhandari, Bilcare Ltd., which started off as a pharma packaging company has diversified into pharma based services, Clinical Trial supply and services, packaging research and has also established clinical research academies in various key markets in India. These achievements were made in the last ten years.


On receiving this honour, Mr. Mohan Bhandari said, ‘I am delighted that finally the industry is recognizing our endeavour in research and packaging and other critical areas of services. With this kind of recognition, we shall move ahead to make novel innovations which would benefit the healthcare industry.’


Bilcare, headquartered in India has spread its roots exponentially to Singapore, UK and US and has established itself as a niche research company with over 55 patents in its kitty. Last week, the company also launched its first Global Research Centre of Excellence with an investment of USD 12 million in Pune. The Global Research Centre of Excellence will have dedicated R&D sections for Packaging Research, Material Research, Analytical Research, Drug Sensitivity Studies and Package Design. For converting the innovations into reality, the Centre is also equipped with Asia’s first integrated Flexo Printing machine and a state of the art pilot plant.


Bilcare’s biggest contribution to the pharmaceutical industry so far, is the anti-counterfeit product. This product will help the pharmaceutical industry in securing their brand, increasing every product’s warranty and traceability, ensuring healthcare compliance and secure the supply management chain apart from eradicating counterfeit.


Out of major investments in nanotechnology research & development happening today, this is one of the first cost effective and useful solutions for the common man.  The technology uses combination of new material with unique magnetic properties and proprietary pattern recognition in a cost effective way to mass manufacture identification tags. These nano-tags are virtually impossible to duplicate with inbuilt magnetic fingerprint technology, which can be read by specially developed magneto-optic readers.  This data is then sent through a normal GPRS cell phone to the Central Server for instant secured authentication, which in turn identifies the pedigree of each product.  


Sourced From: Corporate Voice|Weber Shandwick

Bilcare stock price

On November 27, 2015, Bilcare closed at Rs 54.65, down Rs 2.5, or 4.37 percent. The 52-week high of the share was Rs 79.75 and the 52-week low was Rs 38.80.

The latest book value of the company is Rs 283.29 per share. At current value, the price-to-book value of the company was 0.19.

Set email alert for
Bilcare Pfizer


video of the day

Dont see mkt going anywhere now; like Bharat Forge: Dipen

Explore Moneycontrol

Copyright © Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of is prohibited.